ストックスクリーナーアプリを入手
124.46
1.09%
-1.41
前日終値:
$125.87
開ける：
$126.13
24時間の取引高:
1.50M
Relative Volume:
0.23
時価総額：
$154.58B
収益：
$29.79B
当期純損益:
$9.22B
株価収益率:
16.93
EPS:
7.3494
ネットキャッシュフロー:
$10.23B
1週間 パフォーマンス:
-3.61%
1か月 パフォーマンス:
-7.74%
6か月 パフォーマンス:
+3.41%
1年 パフォーマンス:
+11.11%
1日の値動き範囲:
$124.29
$126.50
1週間の範囲:
$121.39
$130.80
52週間の値動き範囲:
$104.46
$157.29
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
124.50 | 156.28B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,146.71 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
239.39 | 573.71B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
224.41 | 397.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.25 | 298.26B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
153.39 | 293.69B | 54.66B | 13.58B | 16.05B | 7.0171 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead donates remdesivir to Uganda for Ebola outbreak response By Investing.com - Investing.com Canada
Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief - Business Wire
UniSuper Management Pty Ltd Sells 124,258 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Vaughan David Investments LLC IL Invests $33.80 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Xponance LLC Has $29.15 Million Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by Sector Gamma AS - MarketBeat
Swiss National Bank Has $417.34 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Te Ahumairangi Investment Management Ltd Sells 8,180 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Meiji Yasuda America Inc Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
Nuveen LLC Boosts Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by DJE Kapital AG - MarketBeat
Aviva PLC Acquires 59,782 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
SF: Rememberance Work Is Future Work: Gilead Commits $3M For Hiv/Aids Education And Preservation - SFGATE
CAR T-Cell Therapy for Non-Hodgkin’s lymphoma Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Gilead Sciences, Kite Pharma, Novartis, BMS, Allogene Therapeut - Barchart.com
Gilead Sciences Inc (GILD) Stock Up 3.6% but GF Value Says Overv - GuruFocus
Gilead (GILD) CMO Dietmar Berger converts RSUs and withholds shares for taxes - Stock Titan
Gilead (GILD) CFO exercises 2,796 RSUs and withholds 1,341 shares for taxes - Stock Titan
Gilead (NASDAQ: GILD) officer reports RSU vesting and tax withholding on Form 4 - Stock Titan
Gilead (GILD) CEO Daniel O'Day exercises RSUs and withholds shares for taxes - Stock Titan
Gilead Sciences Inc (GILD) Stock Up 3.6% but GF Value Says Overvalued -- GF Score: 76/100 - GuruFocus
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership - Gilead Sciences
Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now? - Insider Monkey
Gilead Sciences Target of Unusually Large Options Trading (NASDAQ:GILD) - MarketBeat
Gilead Sciences Inc Stock (GILD) Moved Up by 3.48% on Jun 11: Key Drivers Unveiled - TradingKey
Johnson Wealth Management LLC Makes New $2.51 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Acquired by LPL Financial LLC - MarketBeat
Cerity Partners LLC Buys 19,673 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline Development - Insider Monkey
Gilead Sciences Inc (GILD) Shares Fall 3.2% -- What GF Score of 76 Tells Investors - GuruFocus
Gilead Sciences Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Gilead Sciences Inc Stock (GILD) Closed Down by 3.12% on Jun 10: What Investors Need To Know - TradingKey
Can Gilead Sciences HIV Franchise Drive Long-Term Growth? - Yahoo Finance
Motley Fool Asset Management LLC Buys 29,394 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Deutsche Bank AG Decreases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by BLI Banque de Luxembourg Investments - MarketBeat
4th Circ. Revives Ex-Gilead Worker's Defamation Suit - Law360
What I Wish I Knew About Hepatitis B: Personal Journeys Out of Asia - Gilead Sciences
Gilead Sciences Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study - Yahoo Finance
Gilead And Merck End Trodelvy-Keytruda Lung Cancer TrialGilead Sciences (NASDAQ:GILD), Merck & Co (NYS - Benzinga
Gilead Balances Trodelvy Setback With Once Weekly HIV Progress - simplywall.st
Gilead’s Mixed Trial News Puts HIV Progress And Oncology Risks In Focus - Yahoo Finance
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies - BioPharma Dive
Calamos Growth & Income Portfolio's Gilead Sciences Inc(GILD) Holding History - GuruFocus
Ex-Gilead Worker Lands New Shot at Defamation Suit Over Firing - Bloomberg Law News
Merck, Gilead score in effort to develop the first weekly HIV pill - Fierce Pharma
As Gilead's Trodelvy stumbles in first-line lung cancer, all eyes turn to Merck, AZ and Daiichi rivals - Fierce Pharma
Gilead and MSD’s once-weekly HIV pill meets primary endpoints in Phase III trials - Clinical Trials Arena
Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble - BioSpace
A Quick Look at Today's Ratings for Gilead Sciences(GILD.US), With a Forecast Between $155 to $165 - Moomoo
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
1.32%
大文字化:
|
ボリューム (24 時間):